Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
Authors:
- M. J. van Den BentMBM. J. van Den Bent
- O. ChinotOCO. Chinot
- W. BoogerdWBW. Boogerd
- J. Bravo MarquesJMJ. Bravo Marques
- M. J. B. TaphoornMTM. J. B. Taphoorn
- J. M. KrosJKJ. M. Kros
- C. C. D. van der RijtCRC. C. D. van der Rijt
- C. J. VechtCVC. J. Vecht
- N. De BeuleNBN. De Beule
- B. BaronBBB. Baron
Open Access
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 14 (4) , 599-602
Abstract
Background: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy. Patients and methods: In a prospective non-randomized multicenter phase II trial patients were treated with TMZ 150 mg/m2 on days 1–5 in cycles of 28 days for 12 cycles. Eligible patients had a recurrence after prior PCV chemotherapy, with measurable and enhancing disease as shown by magnetic resonance imaging. Pathology and all responses were centrally reviewed. Results: Thirty-two eligible patients were included. In four patients the pathology review did not confirm the presence of an OD or OA. Twelve of 24 patients [50%, 95% confidence interval (CI) 29% to 71%] evaluable for response to first-line PCV chemotherapy had responded to PCV. Temozolomide was in general well tolerated; the most frequent side-effects were hematological. One patient discontinued treatment due to toxicity. In seven of 28 patients (25%, 95% CI 11% to 45%) with histologically confirmed OD an objective response to TMZ was observed. Median time to progression for responding patients was 8.0 months. After 6 and 12 months from the start of treatment, 29% and 11% of patients, respectively, were still free from progression. Conclusions: TMZ may be regarded as the preferred second-line treatment in OD after failure of PCV chemotherapy. Further studies on TMZ in OD are indicated.Keywords
This publication has 16 references indexed in Scilit:
- Temozolomide chemotherapy in recurrent oligodendrogliomaNeurology, 2001
- Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II studyAnnals of Oncology, 2001
- Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJournal of Clinical Oncology, 1999
- Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendrogliomaNeurology, 1999
- PCV Chemotherapy for Recurrent Oligodendrogliomas and OligoastrocytomasNeurosurgery, 1998
- Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapyNeurology, 1998
- Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958